Dr. Reisa Sperling, director of the Alzheimer's disease center at Brigham and Women's Hospital in Boston, will be heading a study that will test an experimental drug from Eli Lilly & Co. called solanezumab. The study, to include 1,000 people with plaque buildup but no signs of dementia, will test whether the drug can prevent the development of Alzheimer's when administered before symptoms manifest. Researchers are also paying close attention to whether the drug can at least hinder the speed of cognitive degeneration.
Study to test solanezumab's potential in preventing Alzheimer's
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|